http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 Oct 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/ZEISS+demonstrates+new+digital+and+visual+enhancements+across+ophthalmic+workflows+at+AAO/27152863.html <div class="xn-content"> <p>ZEISS Medical Technology will showcase its latest innovations and digital technologies at AAO, including:</p> <ol type="1"> <li><b>Connected cataract workflow –</b><b>ZEISS VERACITY Surgery Planner reaches 3 million surgical cases planned</b> through cloud-based software, supporting surgical efficiency built on automation and accurate data.</li> http://www.streetinsider.com/Press+Releases/ZEISS+demonstrates+new+digital+and+visual+enhancements+across+ophthalmic+workflows+at+AAO/27152863.html Tue, 06 Oct 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/PRNewswire/ZEISS+demonstrates+new+digital+and+visual+enhancements+across+ophthalmic+workflows+at+AAO/27152863.html <div class="xn-content"> <p>ZEISS Medical Technology will showcase its latest innovations and digital technologies at AAO, including:</p> <ol type="1"> <li><b>Connected cataract workflow –</b><b>ZEISS VERACITY Surgery Planner reaches 3 million surgical cases planned</b> through cloud-based software, supporting surgical efficiency built on automation and accurate data.</li> http://www.streetinsider.com/PRNewswire/ZEISS+demonstrates+new+digital+and+visual+enhancements+across+ophthalmic+workflows+at+AAO/27152863.html Tue, 06 Oct 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/Investing/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html <p>Investing.com -- Goldman Sachs (ETR: AFXG) (OTC: CZMWY) has downgraded Carl Zeiss Meditec to a Sell rating from its previous Neutral rating, with a revised price target of €23.00 down from €27.00 previously. The analysts say the new target price reflects around 26% downside, while Goldman Sachs’ average upside estimate for the overall European Medtech coverage is 22%.</p> <p></p> <p>Zeiss is trading above its 10-year relative valuation range, and well above the organic growth and P/E multiple relationships in the sector. According to firm analysts, the company’s current valuation doesn’t reflect the fundamental outlook, and they see the risk/reward for Zeiss skewed http://www.streetinsider.com/Investing/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html Mon, 05 Oct 2026 10:06:47 -0400 AFXG CZMWY http://www.streetinsider.com/General+News/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html <p>Investing.com -- Goldman Sachs (ETR: AFXG) (OTC: CZMWY) has downgraded Carl Zeiss Meditec to a Sell rating from its previous Neutral rating, with a revised price target of €23.00 down from €27.00 previously. The analysts say the new target price reflects around 26% downside, while Goldman Sachs’ average upside estimate for the overall European Medtech coverage is 22%.</p> <p></p> <p>Zeiss is trading above its 10-year relative valuation range, and well above the organic growth and P/E multiple relationships in the sector. According to firm analysts, the company’s current valuation doesn’t reflect the fundamental outlook, and they see the risk/reward for Zeiss skewed http://www.streetinsider.com/General+News/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html Mon, 05 Oct 2026 10:06:47 -0400 AFXG CZMWY http://www.streetinsider.com/Investing/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html <p>Investing.com -- Goldman Sachs (ETR: AFXG) (OTC: CZMWY) has downgraded Carl Zeiss Meditec to a Sell rating from its previous Neutral rating, with a revised price target of €23.00 down from €27.00 previously. The analysts say the new target price reflects around 26% downside, while Goldman Sachs’ average upside estimate for the overall European Medtech coverage is 22%.</p> <p></p> <p>Zeiss is trading above its 10-year relative valuation range, and well above the organic growth and P/E multiple relationships in the sector. According to firm analysts, the company’s current valuation doesn’t reflect the fundamental outlook, and they see the risk/reward for Zeiss skewed http://www.streetinsider.com/Investing/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html Mon, 05 Oct 2026 10:06:47 -0400 AFXG CZMWY http://www.streetinsider.com/General+News/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html <p>Investing.com -- Goldman Sachs (ETR: AFXG) (OTC: CZMWY) has downgraded Carl Zeiss Meditec to a Sell rating from its previous Neutral rating, with a revised price target of €23.00 down from €27.00 previously. The analysts say the new target price reflects around 26% downside, while Goldman Sachs’ average upside estimate for the overall European Medtech coverage is 22%.</p> <p></p> <p>Zeiss is trading above its 10-year relative valuation range, and well above the organic growth and P/E multiple relationships in the sector. According to firm analysts, the company’s current valuation doesn’t reflect the fundamental outlook, and they see the risk/reward for Zeiss skewed http://www.streetinsider.com/General+News/Goldman+cuts+Carl+Zeiss+Meditec+as+%E2%80%98valuation+disconnected+from+fundamentals%E2%80%99/27147047.html Mon, 05 Oct 2026 10:06:47 -0400 AFXG CZMWY http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Downgrades/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Downgrades/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Intl+Ratings/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Downgrades/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Downgrades/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html <p>Goldman Sachs analyst Richard Felton downgraded Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) from Neutral to Sell with a price target of EUR23.00 (from EUR27.00).</p><p>The analyst comments: “We downgrade Carl Zeiss Meditec to Sell from Neutral with a €23 PT (-26% downside vs 22% avg upside for our coverage). Our thesis rests primarily on the disconnect between current valuation relative to our top-line growth outlook: shares now trade at 23.6x NTM P/E and have re-rated YTD alongside a deteriorating outlook/visibility for top-line growth (GSe +3.2% OSG in FY27-29) and meaningful negative EPS revisions (-54%/-45%/-39% FY26/27/28 EPS). We believe the re-rating http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+to+Sell/27144535.html Mon, 05 Oct 2026 01:53:24 -0400 CZMWY http://www.streetinsider.com/Press+Releases/From+diagnosis+to+treatment%2C+ZEISS+introduces+innovations+across+ZEISS+Retina+Workflow+at+EURETINA+2026/27099728.html <div class="xn-content"> <p>ZEISS Medical Technology advances its <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4782122-1&amp;h=2089936458&amp;u=https%3A%2F%2Fwww.zeiss.com%2Fmeditec%2Fen%2Fworkflows%2Fretina-workflow-idi-retina.html%3Futm_source%3Dgoogle-paid%26utm_medium%3Dtext-ad%26utm_campaign%3Dc-00014471-USA-Always-on%26utm_term%3Dsearch-network%26utm_content%3Drta%26gad_source%3D1%26gad_campaignid%3D22037538207%26gbraid%3D0AAAAAD2N4uiOapJLraAZ1MWki3yObVa02%26gclid%3DEAIaIQobChMIzp2ygpTvlgMV4AWtBh2xJSpHEAAYASAAEgL2APD_BwE&amp;a=ZEISS+Retina+Workflow" target="_blank" rel="nofollow">ZEISS Retina Workflow</a> with digital and surgical enhancements, and new imaging technologies, including:</p> <ul type="disc"> <li><b>Diagnostics:</b> ZEISS expands its retinal imaging portfolio with the new ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device.<br /> </li> http://www.streetinsider.com/Press+Releases/From+diagnosis+to+treatment%2C+ZEISS+introduces+innovations+across+ZEISS+Retina+Workflow+at+EURETINA+2026/27099728.html Thu, 24 Sep 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/PRNewswire/From+diagnosis+to+treatment%2C+ZEISS+introduces+innovations+across+ZEISS+Retina+Workflow+at+EURETINA+2026/27099728.html <div class="xn-content"> <p>ZEISS Medical Technology advances its <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4782122-1&amp;h=2089936458&amp;u=https%3A%2F%2Fwww.zeiss.com%2Fmeditec%2Fen%2Fworkflows%2Fretina-workflow-idi-retina.html%3Futm_source%3Dgoogle-paid%26utm_medium%3Dtext-ad%26utm_campaign%3Dc-00014471-USA-Always-on%26utm_term%3Dsearch-network%26utm_content%3Drta%26gad_source%3D1%26gad_campaignid%3D22037538207%26gbraid%3D0AAAAAD2N4uiOapJLraAZ1MWki3yObVa02%26gclid%3DEAIaIQobChMIzp2ygpTvlgMV4AWtBh2xJSpHEAAYASAAEgL2APD_BwE&amp;a=ZEISS+Retina+Workflow" target="_blank" rel="nofollow">ZEISS Retina Workflow</a> with digital and surgical enhancements, and new imaging technologies, including:</p> <ul type="disc"> <li><b>Diagnostics:</b> ZEISS expands its retinal imaging portfolio with the new ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device.<br /> </li> http://www.streetinsider.com/PRNewswire/From+diagnosis+to+treatment%2C+ZEISS+introduces+innovations+across+ZEISS+Retina+Workflow+at+EURETINA+2026/27099728.html Thu, 24 Sep 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/Press+Releases/ZEISS+expands+retinal+imaging+portfolio+with+new+ZEISS+ALTA+DUO+300/27073550.html <div class="xn-content"> <p>ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices.</p> <p><span class="legendSpanClass">JENA, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>Sept. 17, 2026</chron></span> /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, announced the expansion of its retinal imaging portfolio with the ZEISS ALTA DUO fully automated, compact, multimodal imaging solution. Combining http://www.streetinsider.com/Press+Releases/ZEISS+expands+retinal+imaging+portfolio+with+new+ZEISS+ALTA+DUO+300/27073550.html Thu, 17 Sep 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/PRNewswire/ZEISS+expands+retinal+imaging+portfolio+with+new+ZEISS+ALTA+DUO+300/27073550.html <div class="xn-content"> <p>ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices.</p> <p><span class="legendSpanClass">JENA, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>Sept. 17, 2026</chron></span> /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, announced the expansion of its retinal imaging portfolio with the ZEISS ALTA DUO fully automated, compact, multimodal imaging solution. Combining http://www.streetinsider.com/PRNewswire/ZEISS+expands+retinal+imaging+portfolio+with+new+ZEISS+ALTA+DUO+300/27073550.html Thu, 17 Sep 2026 09:00:00 -0400 CZMWY http://www.streetinsider.com/Intl+Ratings/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/Intl+Ratings/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/Intl+Ratings/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/Intl+Ratings/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/New+Coverage/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html <p>Morgan Stanley analyst Jack Reynolds-Clark initiates coverage on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) with a Underweight rating and a price target of EUR25.88.</p><p>The analyst comments: “Although the product portfolio remains differentiated and supports a credible long-term recovery story, we see 10% downside to FY2026/27 EBITA expectations. With valuation still at a 10% premium vs peers, we think a further estimate reset would likely drive a de-rating. Our thesis is driven by three factors:</p><p>1. China refractive and cataract remain structurally weaker than consensus assumes, with refractive contributing an estimated 20-25% of group EBITA and VBP continuing to pressure cataract http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Starts+Carl+Zeiss+Meditec+AG+%28AFX%3AGR%29+%28CZMWY%29+at+Underweight/27014550.html Wed, 02 Sep 2026 03:16:28 -0400 CZMWY http://www.streetinsider.com/FDA/Zeiss+Clinic+360+wins+FDA+clearance+for+ophthalmic+data+software/26947991.html <p>Carl Zeiss Meditec AG (Frankfurt: AFX) announced that its ZEISS CLINIC 360 software has received 510(k) clearance from the U.S. Food and Drug Administration. The cloud and browser-based software is designed for ophthalmic clinical workflows and is expected to be available in the U.S. in early fall 2026.</p><p>ZEISS CLINIC 360 aggregates data from diagnostic devices, electronic medical records, and practice systems into a single patient view. The software supports DICOM-enabled devices, including ZEISS products such as CIRRUS, CLARUS, and HFA, as well as third-party devices. It includes tools for monitoring disease progression, such as color-coded alerts and trend analysis for http://www.streetinsider.com/FDA/Zeiss+Clinic+360+wins+FDA+clearance+for+ophthalmic+data+software/26947991.html Wed, 19 Aug 2026 09:01:08 -0400 AFX CZMWY http://www.streetinsider.com/FDA/Zeiss+Clinic+360+wins+FDA+clearance+for+ophthalmic+data+software/26947991.html <p>Carl Zeiss Meditec AG (Frankfurt: AFX) announced that its ZEISS CLINIC 360 software has received 510(k) clearance from the U.S. Food and Drug Administration. The cloud and browser-based software is designed for ophthalmic clinical workflows and is expected to be available in the U.S. in early fall 2026.</p><p>ZEISS CLINIC 360 aggregates data from diagnostic devices, electronic medical records, and practice systems into a single patient view. The software supports DICOM-enabled devices, including ZEISS products such as CIRRUS, CLARUS, and HFA, as well as third-party devices. It includes tools for monitoring disease progression, such as color-coded alerts and trend analysis for http://www.streetinsider.com/FDA/Zeiss+Clinic+360+wins+FDA+clearance+for+ophthalmic+data+software/26947991.html Wed, 19 Aug 2026 09:01:08 -0400 AFX CZMWY http://www.streetinsider.com/Press+Releases/ZEISS+CLINIC+360+receives+FDA+510k+clearance%2C+amplifying+patient+care+through+simplified+clinical+insights/26947935.html <div class="xn-content"> <p>The ZEISS CLINIC 360 all-in-one browser-based software solution aggregates clinical data at scale and powers advanced analytics for streamlined ophthalmic workflows, providing clinicians with more time for personalizing patient care.</p><p><span class="legendSpanClass">JENA, <location value="LC/de" idsrc="xmltag.org" >Germany</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- ZEISS Medical Technology, one of the world's leading medical technology companies, today announced the 510k clearance from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org" >FDA</span>) for ZEISS CLINIC 360¹. An all-in-one cloud and browser-based software solution, ZEISS CLINIC 360 combines diagnostic and medical data into a comprehensive patient view. By making relevant information easy http://www.streetinsider.com/Press+Releases/ZEISS+CLINIC+360+receives+FDA+510k+clearance%2C+amplifying+patient+care+through+simplified+clinical+insights/26947935.html Wed, 19 Aug 2026 09:00:00 -0400 A.03578601 A.06822034 A.16161087 A.37332261 AFX CZMWY O.00244597 O.01229783 O.15789788 O.20026344 O.22986476